Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22506221 | 0.87 | FPR2 (1.00) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL14937931 | 0.87 | FPR2 (1.00) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL14948919 | 0.87 | FPR2 (1.00) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL11200596 | 0.83 | FPR2 (0.57) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL11055286 | 0.83 | FPR2 (0.57) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL23129901 | 0.81 | FPR2 (0.72) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL20484217 | 0.81 | FPR2 (0.65) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL14903118 | 0.81 | FPR2 (0.65) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL28348165 | 0.80 | FPR2 (0.77) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL16588643 | 0.80 | FPR2 (0.77) | FPR2LMNAALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964213-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | claimed |
| EP-2964214-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2016-01-13 | — | — | EP | claimed |
| WO-2014138037-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| WO-2014138046-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| EP-3795148-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2014138037-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138046-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885LMNA 3347/4885ALDH1A1 4552/4885 |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885LMNA 3347/4885ALDH1A1 4552/4885 |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885LMNA 3347/4885ALDH1A1 4552/4885 |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885LMNA 3347/4885ALDH1A1 4552/4885 |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885LMNA 4475/4885ALDH1A1 4021/4885 |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | FPR2, FPR1, FPR3 | FPR2 1/4885LMNA 4475/4885ALDH1A1 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.